Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries

被引:13
|
作者
Robles, Claudia [1 ]
Bruni, Laia [1 ]
Acera, Amelia [2 ,3 ]
Riera, Joan Carles [4 ]
Prats, Laia [5 ]
Poljak, Mario [6 ]
Mlakar, Jana [6 ]
Valencak, Anja Ostrbenk [6 ]
Eriksson, Tiina [7 ]
Lehtinen, Matti [7 ]
Louvanto, Karolina [8 ]
Hortlund, Maria [9 ]
Dillner, Joakim [9 ]
Faber, Mette T. [10 ]
Munk, Christian [10 ]
Kjaer, Susanne K. [10 ,11 ]
Petry, Karl Ulrich [12 ]
Denecke, Agnieszka [12 ]
Xu, Lan [13 ]
Arbyn, Marc [13 ]
Cadman, Louise [14 ]
Cuzick, Jack [14 ]
Dalstein, Veronique [15 ,16 ]
Clavel, Christine [15 ,16 ]
de Sanjose, Silvia [17 ,18 ]
Bosch, F. Xavier [1 ,19 ]
机构
[1] Catalan Inst Oncol, IDIBELL, Canc Epidemiol Res Programme, Barcelona, Spain
[2] Inst Catala Salut, Atencio Salut Sexual & Reprod ASSIR SAP Cerdanyol, Barcelona, Spain
[3] IDIAP Jordi Gol, Unitat Suport Recerca Metropolitana Nord, Barcelona, Spain
[4] Inst Catala Salut, Atencio Salut Sexual & Reprod ASSIR SAP Girones P, Girona, Spain
[5] Ctr Ginecol Gine 3, Barcelona, Spain
[6] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia
[7] Univ Tampere, Dept Hlth Sci, Tampere, Finland
[8] Univ Tampere, Dept Obstet & Gynecol, Tampere, Finland
[9] Karolinska Inst, Dept Lab Med, Stockholm, Sweden
[10] Danish Canc Soc, Res Ctr, Unit Virus Lifestyle & Genes, Copenhagen, Denmark
[11] Univ Copenhagen, Rigshosp, Dept Gynecol, Copenhagen, Denmark
[12] Klinikum Wolfsburg, Dept Gynecol Oncol, Wolfsburg, Germany
[13] Sciensano, Belgian Canc Ctr, Unit Canc Epidemiol, Brussels, Belgium
[14] Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, London, England
[15] Univ Reims, INSERM P3Ce11, Ctr Hosp Univ CHU Reims, Reims, France
[16] SFR CAP SANTE, UMR S 1250, Reims, France
[17] PATH, Seattle, WA USA
[18] Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Barcelona, Spain
[19] Univ Oberta Catalunya UOC, Fac Hlth Sci, Barcelona, Spain
关键词
D O I
10.1016/j.amepre.2020.08.032
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: Human papillomavirus-vaccinated cohorts, irrespective of age, will likely reduce their subsequent screening requirements, thus opening opportunities for global cost reduction and program sustainability. The determinants of uptake and completion of a 3-dose human papillomavirus vaccination program by adult women in a European context were estimated. Study design: This was an intervention study. Setting/participants: Study participants were women aged 25-45 years, attending opportunistic or population-based cervical cancer screening in Belgium, Denmark, Finland, France, Germany, Slovenia, Spain, Sweden, and the United Kingdom between April 2016 and May 2018. Intervention: Study participants completed a questionnaire on awareness and attitudes on adult female human papillomavirus vaccination and were invited to receive free human papillomavirus vaccination. Main outcome measures: Main outcome measures were acceptance, uptake, and completion of vaccination schedule. Determinants of vaccine uptake were explored using multilevel logistic models in 2019. Results: Among 3,646 participants, 2,748 (range by country=50%-96%) accepted vaccination, and 2,151 (range=30%-93%) received the full vaccination course. The factors associated with higher vaccine acceptance were previous awareness of adult female (OR=1.22, 95% CI=1.00, 1.48) and male (OR=1.59, 95% CI=1.28, 1.97) vaccination. Women in stable relationships (OR=0.56, 95% CI=0.45, 0.69) or with higher educational level (OR=0.76, 95% CI=0.63, 0.93) were more likely to refuse vaccination. Recruitment by postal invitation versus personal invitation from a healthcare professional resulted in lower vaccine acceptance (OR=0.13, 95% CI=0.02, 0.76). Vaccination coverage of >70% of adolescent girls in national public programs was of borderline significance in predicting human papillomavirus vaccine uptake (OR=3.23, 95% CI=0.95, 10.97). The main reasons for vaccine refusal were vaccine safety concerns (range=30%-59%) and the need for more information on human papillomavirus vaccines (range=1%-72%). No safety issues were experienced by vaccinated women. Conclusions: Acceptance and schedule completion were largely dependent on recruitment method, achieved coverage of national vaccination programs, and personal relationship status. Knowledge of benefits and safety reassurance may be critical to expanding vaccination target ages. Study results suggest that there are no major opinion barriers in adult women to human papillomavirus vaccination, especially when vaccination is offered face to face in healthcare settings. (C) 2020 American Journal of Preventive Medicine. Published by Elsevier Inc.
引用
收藏
页码:478 / 487
页数:10
相关论文
共 50 条
  • [1] Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile
    Priscilla Brebi
    Carmen Gloria Ili
    Alejandra Andana
    Doris Menzel
    Jaime Lopez
    Pablo Guzman
    Angelica Melo
    Kurt Buchegger
    Juan C. Roa
    [J]. BMC Cancer, 17
  • [2] Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile
    Brebi, Priscilla
    Gloria Ili, Carmen
    Andana, Alejandra
    Menzel, Doris
    Lopez, Jaime
    Guzman, Pablo
    Melo, Angelica
    Buchegger, Kurt
    Roa, Juan C.
    [J]. BMC CANCER, 2017, 17
  • [3] Prevaccination Distribution of Human Papillomavirus Types in Women Attending at Cervical Cancer Screening in Belgium
    Arbyn, Marc
    Benoy, Ina
    Simoens, Cindy
    Bogers, Johannes
    Beutels, Philippe
    Depuydt, Christophe
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (01) : 321 - 330
  • [4] Cervical cancer screening in the time of the human papillomavirus vaccine
    Sheinfeld, Gorin S.
    Franco, R.
    Hajiani, F.
    Westhoff, C.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (02) : 358 - 358
  • [5] Genotypic diversity of anogenital human papillomavirus in women attending cervical cancer screening in Harare, Zimbabwe
    Mandishora, Racheal S. Dube
    Christiansen, Irene K.
    Chin'ombe, Nyasha
    Duri, Kerina
    Ngara, Bernard
    Rounge, Trine B.
    Meisal, Roger
    Ambur, Ole H.
    Palefsky, Joel M.
    Stray-Pedersen, Babill
    Chirenje, Zvavahera M.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (09) : 1671 - 1677
  • [6] Determinants in the uptake of the human papillomavirus vaccine: a systematic review based on European studies
    de Casadevante, Victoria Fernandez
    Cuesta, Julita Gil
    Cantarero-Arevalo, Lourdes
    [J]. FRONTIERS IN ONCOLOGY, 2015, 5
  • [7] Primary prevention of cervical cancer in women: Human papillomavirus vaccine
    O'Neill, Alice M.
    Dwyer, Roisin
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2023, 281 : 29 - 31
  • [8] The human papillomavirus (HPV) vaccine and cervical cancer: Uptake and next steps
    Sherri N. Sheinfeld Gorin
    Beth A. Glenn
    Rebecca B. Perkins
    [J]. Advances in Therapy, 2011, 28 : 615 - 639
  • [9] The human papillomavirus (HPV) vaccine and cervical cancer: Uptake and next steps
    Gorin, Sherri N. Sheinfeld
    Glenn, Beth A.
    Perkins, Rebecca B.
    [J]. ADVANCES IN THERAPY, 2011, 28 (08) : 615 - 639
  • [10] Apropos Knowledge and Attitudes of Adult Peruvian Women vis-a-vis Human Papillomavirus, Cervical Cancer, and the Human Papillomavirus Vaccine
    Arya, Subhash C.
    Agarwal, Nirmala
    [J]. JOURNAL OF LOWER GENITAL TRACT DISEASE, 2010, 14 (04) : 395 - 395